Erythropoiesis-Stimulating Agents and the Risk of Vision-Threatening Diabetic Retinopathy

References

• Congdon N, O’Colmain B, Klaver CCW, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–485.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B. Vision disorders in diabetes. In: National Diabetes Data GroupDiabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:pp. 293–337.
   Google Scholar
• Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
   PubMed Web of Science ®Google Scholar
• Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–2146. doi:10.1001/jama.2015.15217.
   PubMed Web of Science ®Google Scholar
• Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126(8):1155–1170. doi: 10.1016/j.ophtha.2019.03.023
   PubMed Web of Science ®Google Scholar
• Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14):e93751. doi:10.1172/jci.insight.93751
   PubMed Web of Science ®Google Scholar
• Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest. 2005;115(1):86–93. doi: 10.1172/JCI22869
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098. doi: 10.1056/NEJMoa065485
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(26):1–14. doi: 10.1056/NEJMoa0907845
   PubMedGoogle Scholar
• KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):331–335. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf
   Google Scholar
• de Lucas Cerrillo AM, Bond WS, Rex TS. Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin. Gene Ther. 2015;22(5):365–373. doi:10.1038/gt.2015.12
   PubMed Web of Science ®Google Scholar
• Feizi S, Alemzadeh-Ansari M, Karimian F, et al. Use of erythropoietin in ophthalmology: a review [published online ahead of print, 2021 Jun 23]. Surv Ophthalmol. 2021;S0039-6257(21):00139–9.
   Google Scholar
• Xie H, Zhang C, Liu D, et al. Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy. Diabetologia. 2021;64(1):211–225. doi: 10.1007/s00125-020-05299-x
   PubMed Web of Science ®Google Scholar
• Chen J, Connor KM, Aderman CM, et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009;50(3):1329–1335. doi: 10.1167/iovs.08-2521
   PubMed Web of Science ®Google Scholar
• Fang JL, Sorita A, Carey WA, et al. Interventions to prevent retinopathy of prematurity: a meta-analysis. Pediatrics. 2016;137(4):e20153387. doi: 10.1542/peds.2015-3387
   PubMed Web of Science ®Google Scholar
• Stahl A, Buchwald A, Martin G, et al. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina. 2010;30(9):1524–1529. doi: 10.1097/IAE.0b013e3181d37539
   PubMed Web of Science ®Google Scholar
• Friedman EA, L’Esperance FA, Brown CD, et al. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease. Kidney Int Suppl. 2003 87;64:S57–S63. 10.1046/j.1523-1755.64.s87.9.x
   Google Scholar
• Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin As a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353(8):782–792. doi: 10.1056/NEJMoa041773
   PubMed Web of Science ®Google Scholar
• Lau M, Prenner JL, Brucker AJ, et al. Accuracy of billing codes used in the therapeutic care of diabetic retinopathy. JAMA Ophthalmol. 2017;135(7):791. doi: 10.1001/jamaophthalmol.2017.1595
   PubMed Web of Science ®Google Scholar
• Muir KW, Gupta C, Gill P, et al. Accuracy of international classification of diseases, ninth revision, clinical modification billing codes for common ophthalmic conditions. JAMA Ophthalmol. 2013;131(1):119–120. doi: 10.1001/jamaophthalmol.2013.577
   PubMed Web of Science ®Google Scholar
• Desai RJ, Solomon DH, Shadick N, et al. Identification of smoking using medicare data–a validation study of claims-based algorithms. Pharmacoepidemiol Drug Saf. 2016;25(4):472–475. doi: 10.1002/pds.3953
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Schneeweiss S, Mogun H, et al. Identification of individuals with CKD from medicare claims data: a validation study. Am J Kidney Dis. 2005;46(2):225–232. doi: 10.1053/j.ajkd.2005.04.029
   PubMed Web of Science ®Google Scholar
• Yu Y, Ying GS, Maguire MG, et al. Association of diagnosis code-based and laboratory results-based kidney function with development of vision threatening diabetic retinopathy. Ophthalmic Epidemiol. 2020;27(6):498–503. doi: 10.1080/09286586.2020.1773869
   PubMed Web of Science ®Google Scholar
• Li Y, Yu Y, VanderBeek BL. Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy. Eye (Lond). 2020;34(5):934–941. doi:10.1038/s41433-019-0617-6
   PubMed Web of Science ®Google Scholar
• Glasheen WP, Renda A, Dong Y. Diabetes complications severity index (DCSI)-Update and ICD-10 translation. J Diabetes Complications. 2017;31(6):1007–1013. doi:10.1016/j.jdiacomp.2017.02.018
   PubMed Web of Science ®Google Scholar
• Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15–23.
   PubMed Web of Science ®Google Scholar
• Leyrat C, Seaman SR, White IR, et al. Propensity score analysis with partially observed covariates: how should multiple imputation be used? Stat Methods Med Res. 2019;28(1):3–19. doi: 10.1177/0962280217713032
   PubMed Web of Science ®Google Scholar
• Shinozaki T, Nojima M. Misuse Of regression adjustment for additional confounders following insufficient propensity score balancing. Epidemiology. 2019;30(4):541–548. doi:10.1097/EDE.0000000000001023
   PubMed Web of Science ®Google Scholar
• Del Vecchio L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin Drug Saf. 2016;15(8):1021–1030. doi:10.1080/14740338.2016.1182494
   PubMed Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301–315. doi: 10.1038/sj.bjc.6605498
   PubMed Web of Science ®Google Scholar
• Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis. 1991;18:76–83.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Cancarini A, Morescalchi F, et al. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. Diabetes Metab. 2014;40(6):445–451. doi: 10.1016/j.diabet.2014.04.005
   PubMed Web of Science ®Google Scholar
• Hosseini SM, Boright AP, Sun L, et al. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum Genet. 2015;134(2):247–257. doi: 10.1007/s00439-014-1517-2
   PubMed Web of Science ®Google Scholar
• Lee KE. Considerations when temporal order is not clear. JAMA Ophthalmol. 2018;136(1):74–75. doi:10.1001/jamaophthalmol.2017.5212
   PubMed Web of Science ®Google Scholar
• Lee WJ, Sobrin L, Kang MH, et al. Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression. Eye (Lond). 2014;28(9):1119–1125. doi: 10.1038/eye.2014.130
   PubMed Web of Science ®Google Scholar
• Vlasschaert MEO, Bejaimal SAD, Hackam DG, et al. Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis. 2011;57(1):29–43. doi: 10.1053/j.ajkd.2010.08.031
   PubMed Web of Science ®Google Scholar